Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
51 participants
INTERVENTIONAL
2024-02-29
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pain management after CXL is essential for optimizing patient outcomes and satisfaction. Systemic painkillers, though not researched enough, may potentially aid in healing and recovery, minimizing complications and discomfort for the patient.
In this study we will provide evidence-based recommendations for clinicians to optimize pain control after CXL in collaboration with pain specialists.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain Management in Corneal Collagen Crosslinking for Keratoconus
NCT02867176
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection
NCT02068430
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
NCT01189864
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
NCT01024322
Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
NCT01643252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gabapentin
This group will receive a combination of drugs including:
Gabapentin, NSAIDS and Paracetamol.
Gabapentin
Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
NSAID
Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Paracetamol
Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Targin
This group will receive a combination of drugs including:
Targin, NSAIDS and Paracetamol.
Targin
Targin 5 mg twice a day after the procedure for 48 hours
NSAID
Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Paracetamol
Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Control
This group will receive a combination of drugs including:
NSAIDS and Paracetamol.
NSAID
Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Paracetamol
Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gabapentin
Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
Targin
Targin 5 mg twice a day after the procedure for 48 hours
NSAID
Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Paracetamol
Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are undergoing CXL treatment
Exclusion Criteria
* Patients under the age of 15
15 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adi Einan-Lifshitz
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shamir Medical Center (Assaf Harofeh)
Be’er Ya‘aqov, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
177-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.